151 related articles for article (PubMed ID: 11746608)
1. Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?
Stoessl AJ
Mov Disord; 2001 Sep; 16(5):804-6. PubMed ID: 11746608
[No Abstract] [Full Text] [Related]
2. TechSight. Imaging. A molecular map for neurodegeneration.
Marek K; Seibyl J
Science; 2000 Jul; 289(5478):409-11. PubMed ID: 10939953
[No Abstract] [Full Text] [Related]
3. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.
Marek K; Jennings D; Seibyl J
Ann Neurol; 2003; 53 Suppl 3():S160-6; discussion S166-9. PubMed ID: 12666107
[No Abstract] [Full Text] [Related]
4. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
5. Nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
Tissingh G; Bergmans P; Winogrodzka A; Stoof JC; Wolters EC; Booij J; Van Royen EA
J Nucl Med; 1997 Aug; 38(8):1271-2. PubMed ID: 9255164
[No Abstract] [Full Text] [Related]
6. The role of radiotracer imaging in Parkinson disease.
Ravina B; Eidelberg D; Ahlskog JE; Albin RL; Brooks DJ; Carbon M; Dhawan V; Feigin A; Fahn S; Guttman M; Gwinn-Hardy K; McFarland H; Innis R; Katz RG; Kieburtz K; Kish SJ; Lange N; Langston JW; Marek K; Morin L; Moy C; Murphy D; Oertel WH; Oliver G; Palesch Y; Powers W; Seibyl J; Sethi KD; Shults CW; Sheehy P; Stoessl AJ; Holloway R
Neurology; 2005 Jan; 64(2):208-15. PubMed ID: 15668415
[TBL] [Abstract][Full Text] [Related]
7. Objective measures for the progression of Parkinson's disease.
Snow B
J Neurol Neurosurg Psychiatry; 2003 Mar; 74(3):287. PubMed ID: 12588908
[No Abstract] [Full Text] [Related]
8. Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? Against.
Frey KA
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):715-7. PubMed ID: 11976814
[No Abstract] [Full Text] [Related]
9. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
[TBL] [Abstract][Full Text] [Related]
10. Physiologic modeling of PET data: quantitative conflict and challenge.
Ichise M; Ballinger JR
J Nucl Med; 1997 Aug; 38(8):1266-7. PubMed ID: 9255162
[No Abstract] [Full Text] [Related]
11. [Striatal 18F-dopa uptake measuring nigrostriatal function].
Otsuka M; Masuda K; Kato M
Nihon Rinsho; 1991 Jul; 49(7):1532-6. PubMed ID: 1909388
[No Abstract] [Full Text] [Related]
12. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.
Leenders KL; Palmer AJ; Quinn N; Clark JC; Firnau G; Garnett ES; Nahmias C; Jones T; Marsden CD
J Neurol Neurosurg Psychiatry; 1986 Aug; 49(8):853-60. PubMed ID: 3091770
[TBL] [Abstract][Full Text] [Related]
13. [PET study using 6-[18F]-fluorodopa in Parkinson's disease].
Nagasawa H; Tanji H; Itoh M; Itoyama Y
Nihon Rinsho; 1997 Jan; 55(1):213-7. PubMed ID: 9014452
[TBL] [Abstract][Full Text] [Related]
14. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
Pirker W
Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
[TBL] [Abstract][Full Text] [Related]
15. Novel observations with FDOPA-PET imaging after early nigrostriatal damage.
Yee RE; Irwin I; Milonas C; Stout DB; Huang SC; Shoghi-Jadid K; Satyamurthy N; Delanney LE; Togasaki DM; Farahani KF; Delfani K; Janson AM; Phelps ME; Langston JW; Barrio JR
Mov Disord; 2001 Sep; 16(5):838-48. PubMed ID: 11746613
[TBL] [Abstract][Full Text] [Related]
16. PET studies of the striatal dopaminergic system in Parkinson's disease (PD).
Piccini P; Turjanski N; Brooks DJ
J Neural Transm Suppl; 1995; 45():123-31. PubMed ID: 8748617
[TBL] [Abstract][Full Text] [Related]
17. Imaging end points for monitoring neuroprotection in Parkinson's disease.
Brooks DJ
Ann Neurol; 2003; 53 Suppl 3():S110-8; discussion S118-9. PubMed ID: 12666103
[TBL] [Abstract][Full Text] [Related]
18. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Bernheimer H; Birkmayer W; Hornykiewicz O; Jellinger K; Seitelberger F
J Neurol Sci; 1973 Dec; 20(4):415-55. PubMed ID: 4272516
[No Abstract] [Full Text] [Related]
19. Parkinson's disease: from brain homogenate to treatment.
Hornykiewicz O
Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
[No Abstract] [Full Text] [Related]
20. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease.
Eidelberg D; Takikawa S; Moeller JR; Dhawan V; Redington K; Chaly T; Robeson W; Dahl JR; Margouleff D; Fazzini E
Ann Neurol; 1993 May; 33(5):518-27. PubMed ID: 8498828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
